Back to News
Market Impact: 0.2
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
Source: globenewswire.com
Healthcare & Biotech
ATYR0101 is undergoing IND-enabling studies, with advancement into the clinic expected in 2027. The findings point to potential for the therapy to disrupt chronic tissue fibrosis, but no clinical results or efficacy figures are provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
- Liquidia (NASDAQ:LQDA) CMO Rajeev Saggar disposes of $262,528 in stock
- Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity
- J&J beats earnings estimates; Middle East conflict weighs on medical-device sales
- Johnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast